Stoke Therapeutics, Inc. (STOK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 5, 2025, by Stoke Therapeutics, Inc. The filing primarily addresses clinical data presentations made at the 2025 American Epilepsy Society (AES) Annual Meeting regarding zorevunersen, an investigational antisense oligonucleotide for Dravet syndrome, developed in collaboration with Biogen International GmbH.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory disclosures under Regulation FD.
Material Changes and Clinical Data
The report details significant clinical findings presented at the AES Annual Meeting:
- Seizure Reduction: Propensity score weighted analysis showed patients receiving two 70mg loading doses of zorevunersen experienced statistically significant reductions in major motor seizure frequency at six months compared to natural history.
- Cognition and Behavior: Continued dosing at 45mg demonstrated improvements in five key Vineland-3 assessments at 18 months, with several reaching statistical significance.
- Durability: Durable effects were observed through 24 months, the longest evaluable timepoint in the BUTTERFLY natural history study.
- EEG Results: Data highlighted dose-dependent decreases in abnormal brain activity, which correlated with a higher probability of meaningful seizure reduction.
Safety Profile and Risks
Safety data from 81 patients across Phase 1/2a and Open Label Extension (OLE) studies indicates:
- Tolerability: The drug was generally well tolerated. Study drug-related treatment emergent adverse events (TEAEs) occurred in 30% of Phase 1/2a patients and 53% of OLE patients.
- CSF Protein Elevations: The most common TEAE was CSF protein elevation (14% in Phase 1/2a; 45% in OLE). Elevations >50 mg/dL occurred in 42% and 86% of patients in respective studies. No clinical manifestations were observed, though one patient discontinued due to this issue.
- Serious Adverse Events: TESAEs were reported in 22% (Phase 1/2a) and 29% (OLE) of patients. All were assessed as unrelated to zorevunersen except for one patient with SUSARs.
- Mortality: Three deaths were reported (two SUDEP, one malnutrition), all assessed as unrelated to the study drug.
Outlook and Management Commentary
Management and Biogen state that the presented data further support the potential of zorevunersen as a disease-modifying medicine for Dravet syndrome. The 6-month seizure reduction data aligns with the Week 28 primary endpoint of the Phase 3 EMPEROR study, and the 18-month cognitive data aligns with a key secondary endpoint of the same study.
Investor Verification Checklist
- Verify the full text of the attached Press Release (Exhibit 99.1) for complete statistical details.
- Review the Phase 3 EMPEROR study design to confirm alignment with the 6-month and 18-month endpoints cited.
- Monitor upcoming regulatory filings for any updates on the Phase 3 trial timeline or enrollment status.
- Assess the clinical significance of CSF protein elevations in the context of long-term treatment safety.